Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer.

PURPOSE Recent studies have indicated that expression of chemokine receptors CXCR4 and CCR7 could be an indicator of the metastatic potential of breast cancer. Expression of CXCR4 and CCR7 along with the biomarkers HER2-neu and epidermal growth factor receptor (EGFR) was investigated in inflammatory breast cancer (IBC) to evaluate their prognostic implications. EXPERIMENTAL DESIGN CXCR4, CCR7, and EGFR were evaluated by immunohistochemical staining (IHC) of paraffin-embedded tissue sections. HER2-neu amplification was assessed by FISH and/or IHC. All patients received chemotherapy, surgery, and radiation. RESULTS Forty-four cases diagnosed with IBC from 1994 to 2002 were included in the study. In all, 18 (40.9%) patients had positive CXCR4, 10 (22.7%) had positive CCR7, 21 (47.7%) had positive HER2-neu, and EGFR was positive in 12 of 40 patients (30%). The 5-year overall survival (OS) was 24.8% for CXCR4-positive disease versus 42.3% for CXCR4-negative patients (P = 0.53) and 20.0% for CCR7-positive disease versus 41.9% for CCR7-negative patients (P = 0.24). EGFR-positive disease had significantly worse OS compared with EGFR-negative disease (P = 0.01). CONCLUSIONS These data demonstrate the expression of growth factor and chemokine receptors in IBC. The expression of these receptors is associated with increased risk of recurrence and death, and thus, they may represent potential therapeutic targets in IBC.

[1]  C. Bucana,et al.  Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Cassone,et al.  Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis , 2005 .

[3]  W. Hohenberger,et al.  Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine receptor CCR7 , 2005, International journal of cancer.

[4]  G. Hortobagyi,et al.  CCR7 and CXCR4 as Novel Biomarkers Predicting Axillary Lymph Node Metastasis in T1 Breast Cancer , 2005, Clinical Cancer Research.

[5]  K. Ang,et al.  Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin‐based neoadjuvant chemotherapy , 2005, Cancer.

[6]  A. Sahin,et al.  CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. , 2005, Cancer research.

[7]  S. Devesa,et al.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. , 2005, Journal of the National Cancer Institute.

[8]  N. Sneige,et al.  Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma , 2005, Cancer.

[9]  S. Allan,et al.  Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Galle,et al.  Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal Cancer , 2005, Clinical Cancer Research.

[11]  Gerardo Botti,et al.  Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma , 2005, Clinical Cancer Research.

[12]  D. Piwnica-Worms,et al.  CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer , 2004, Cancer Research.

[13]  Luc Y Dirix,et al.  Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification , 2004, Clinical Cancer Research.

[14]  F. Bertucci,et al.  Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy , 2004, Cancer Research.

[15]  G. Hortobagyi,et al.  Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. , 2004, Cancer cell.

[16]  Rosette Lidereau,et al.  Molecular Profiling of Inflammatory Breast Cancer , 2004, Clinical Cancer Research.

[17]  G. Hortobagyi,et al.  p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer , 2004, Clinical Cancer Research.

[18]  G. Hortobagyi,et al.  Prognostic value of P53, MDM‐2, and MUC‐1 for patients with inflammatory breast carcinoma , 2004, Cancer.

[19]  Tae-Hee Lee,et al.  Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. , 2004, Molecular cancer research : MCR.

[20]  S. Merajver,et al.  Validation of a Tissue Microarray to Study Differential Protein Expression in Inflammatory and Non-Inflammatory Breast Cancer , 2004, Breast Cancer Research and Treatment.

[21]  F. André,et al.  Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  M. Dowsett,et al.  High incidence of HER-2 positivity in inflammatory breast cancer. , 2004, Breast.

[23]  F. Bertucci,et al.  Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’ , 2004, The Journal of pathology.

[24]  T. Godfrey,et al.  Expression Pattern of Chemokine Receptor 6 (CCR6) and CCR7 in Squamous Cell Carcinoma of the Head and Neck Identifies a Novel Metastatic Phenotype , 2004, Cancer Research.

[25]  H. Band,et al.  Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells , 2004, Oncogene.

[26]  M. V. van Velthuysen,et al.  Validation of tissue array technology in head and neck squamous cell carcinoma , 2003, Head & neck.

[27]  M. Imamura,et al.  Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  W. Anderson,et al.  Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Nakshatri,et al.  NF-κ B Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4* , 2003, Journal of Biological Chemistry.

[30]  I. Takanami.  Overexpression of CCR7 mRNA in nonsmall cell lung cancer: Correlation with lymph node metastasis , 2003, International journal of cancer.

[31]  G. Hortobagyi,et al.  Update on the management of inflammatory breast cancer. , 2003, The oncologist.

[32]  E. van Marck,et al.  Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression , 2003, British Journal of Cancer.

[33]  E. Topuz,et al.  Inflammatory Breast Cancer: Results of Antracycline‐Based Neoadjuvant Chemotherapy , 2003, The breast journal.

[34]  R. Bachelder,et al.  Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. , 2002, Cancer research.

[35]  S. Steinberg,et al.  Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  R. Anderson,et al.  Genes involved in breast cancer metastasis to bone , 2002, Cellular and Molecular Life Sciences CMLS.

[37]  M. Rahbar,et al.  Case Control Study of Prognostic Markers and Disease Outcome in Inflammatory Carcinoma Breast: A Unique Clinical Experience , 2001, The breast journal.

[38]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Ratajczak,et al.  The SDF‐1‐CXCR4 Axis Stimulates VEGF Secretion and Activates Integrins but does not Affect Proliferation and Survival in Lymphohematopoietic Cells , 2001, Stem cells.

[40]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[41]  S. Merajver,et al.  RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. , 2000, Cancer research.

[42]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[43]  A. Buzdar,et al.  Inflammatory breast carcinoma incidence and survival , 1998, Cancer.

[44]  M S Pepe,et al.  Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? , 1993, Statistics in medicine.

[45]  T. Hakes,et al.  Inflammatory breast cancer. , 1991, Archives of surgery.

[46]  M. Mathieu,et al.  Structure and expression of c‐erbB‐2 and EGF receptor genes in inflammatory and non‐inflammatory breast cancer: Prognostic significance , 1989, International journal of cancer.

[47]  A. Sahin,et al.  Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow , 2005, Clinical & Experimental Metastasis.

[48]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[49]  G. Hortobagyi,et al.  Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center , 1997, Cancer Chemotherapy and Pharmacology.